108 related articles for article (PubMed ID: 22498644)
1. Involvement of ubiquitination in the decrease of intestinal P-glycoprotein in a streptozotocin-induced diabetic mouse model.
Nawa A; Fujita-Hamabe W; Tokuyama S
Drug Metab Pharmacokinet; 2012; 27(5):548-52. PubMed ID: 22498644
[TBL] [Abstract][Full Text] [Related]
2. [Nitric oxide synthase-mediated alteration of intestinal P-glycoprotein under hyperglycemic stress].
Nawa A; Fujita-Hamabe W; Nakamoto K; Tokuyama S
Yakugaku Zasshi; 2011 Apr; 131(4):487-92. PubMed ID: 21467785
[TBL] [Abstract][Full Text] [Related]
3. [Altered intestinal P-glycoprotein expression levels affect pharmacodynamics under diabetic condition].
Nawa A; Fujita-Hamabe W; Kisioka S; Tokuyama S
Yakugaku Zasshi; 2012; 132(2):161-6. PubMed ID: 22293693
[TBL] [Abstract][Full Text] [Related]
4. Regulatory action of nitric oxide synthase on ileal P-glycoprotein expression under streptozotocin-induced diabetic condition.
Nawa A; Fujita-Hamabe W; Tokuyama S
Biol Pharm Bull; 2011; 34(3):436-8. PubMed ID: 21372399
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of intestinal P-glycoprotein increases the analgesic effects of oral morphine in a streptozotocin-induced diabetic mouse model.
Nawa A; Fujita-Hamabe W; Kishioka S; Tokuyama S
Drug Metab Pharmacokinet; 2011; 26(6):584-91. PubMed ID: 21878740
[TBL] [Abstract][Full Text] [Related]
6. Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions.
Nawa A; Fujita Hamabe W; Tokuyama S
Life Sci; 2010 Mar; 86(11-12):402-9. PubMed ID: 20097209
[TBL] [Abstract][Full Text] [Related]
7. Altered intestinal P-glycoprotein expression levels in a monosodium glutamate-induced obese mouse model.
Nawa A; Fujita-Hamabe W; Tokuyama S
Life Sci; 2011 Dec; 89(23-24):834-8. PubMed ID: 21983297
[TBL] [Abstract][Full Text] [Related]
8. FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin--proteasome pathway in cancer cells.
Katayama K; Noguchi K; Sugimoto Y
Cancer Sci; 2013 Jun; 104(6):694-702. PubMed ID: 23465077
[TBL] [Abstract][Full Text] [Related]
9. Changes in the localization of ileal P-glycoprotein induced by intestinal ischemia/reperfusion.
Takizawa Y; Kishimoto H; Kitazato T; Tomita M; Hayashi M
Biol Pharm Bull; 2011; 34(3):408-14. PubMed ID: 21372393
[TBL] [Abstract][Full Text] [Related]
10. Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats.
Zhang LL; Lu L; Jin S; Jing XY; Yao D; Hu N; Liu L; Duan R; Liu XD; Wang GJ; Xie L
Acta Pharmacol Sin; 2011 Jul; 32(7):956-66. PubMed ID: 21685928
[TBL] [Abstract][Full Text] [Related]
11. Aβ40 Reduces P-Glycoprotein at the Blood-Brain Barrier through the Ubiquitin-Proteasome Pathway.
Hartz AM; Zhong Y; Wolf A; LeVine H; Miller DS; Bauer B
J Neurosci; 2016 Feb; 36(6):1930-41. PubMed ID: 26865616
[TBL] [Abstract][Full Text] [Related]
12. Changes in PtdIns(4,5)P2 induced by etoposide treatment modulates small intestinal P-glycoprotein via radixin.
Kobori T; Harada S; Nakamoto K; Tokuyama S
Biol Pharm Bull; 2014; 37(7):1124-31. PubMed ID: 24989004
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide-regulated proteolysis of human CYP2B6 via the ubiquitin-proteasome system.
Lee CM; Tripathi S; Morgan ET
Free Radic Biol Med; 2017 Jul; 108():478-486. PubMed ID: 28427998
[TBL] [Abstract][Full Text] [Related]
14. A double-edged sword role for ubiquitin-proteasome system in brain stem cardiovascular regulation during experimental brain death.
Wu CH; Chan JY; Chan SH; Chang AY
PLoS One; 2011; 6(11):e27404. PubMed ID: 22110641
[TBL] [Abstract][Full Text] [Related]
15. Functional alterations of intestinal P-glycoprotein under diabetic conditions.
Kobori T; Harada S; Nakamoto K; Tokuyama S
Biol Pharm Bull; 2013; 36(9):1381-90. PubMed ID: 23995645
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein activation by 1-(propan-2-ylamino)-4-propoxy-9H-thioxanthen-9-one (TX5) in rat distal ileum: ex vivo and in vivo studies.
Rocha-Pereira C; Ghanem CI; Silva R; Casanova AG; Duarte-Araújo M; Gonçalves-Monteiro S; Sousa E; Bastos ML; Remião F
Toxicol Appl Pharmacol; 2020 Jan; 386():114832. PubMed ID: 31756430
[TBL] [Abstract][Full Text] [Related]
17. Fructose-induced metabolic syndrome decreases protein expression and activity of intestinal P-glycoprotein.
Novak A; Godoy YC; Martinez SA; Ghanem CI; Celuch SM
Nutrition; 2015 Jun; 31(6):871-6. PubMed ID: 25933496
[TBL] [Abstract][Full Text] [Related]
18. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.
Ogihara T; Kamiya M; Ozawa M; Fujita T; Yamamoto A; Yamashita S; Ohnishi S; Isomura Y
Drug Metab Pharmacokinet; 2006 Jun; 21(3):238-44. PubMed ID: 16858128
[TBL] [Abstract][Full Text] [Related]
19. RSK1 protects P-glycoprotein/ABCB1 against ubiquitin-proteasomal degradation by downregulating the ubiquitin-conjugating enzyme E2 R1.
Katayama K; Fujiwara C; Noguchi K; Sugimoto Y
Sci Rep; 2016 Oct; 6():36134. PubMed ID: 27786305
[TBL] [Abstract][Full Text] [Related]
20. CHIP facilitates ubiquitination of inducible nitric oxide synthase and promotes its proteasomal degradation.
Chen L; Kong X; Fu J; Xu Y; Fang S; Hua P; Luo L; Yin Z
Cell Immunol; 2009; 258(1):38-43. PubMed ID: 19362296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
